欧洲风湿科医生与axSpA患者对疾病管理和治疗满意度的视角
该横断面调查覆盖法、德、意、西、英五国268名风湿科医生及其2165例axSpA患者,其中538例患者完成配对问卷。尽管77%患者已接受改善病情进阶治疗,仍有35%晨僵、25%炎性背/髋/臀痛和25%疲劳;医患对疾病严重度(加权一致率86%,κ=0.515)和治疗满意度呈中度一致,但治疗目标不同:医生多追求低疾病活动度(76%),患者多追求缓解疼痛(61%)。
要点
- 尽管77%患者已用进阶治疗,35%仍有晨僵、25%有炎性背/髋/臀痛、25%有疲劳。
- 医患对疾病严重度加权一致率86%(κ=0.515),对治疗满意度亦呈中度一致。
- 医生最常见治疗目标为低疾病活动度(76%),患者最常见目标为缓解疼痛(61%)。
核心结论
- 医患对axSpA疾病严重度和治疗满意度的感知呈中度一致,但对治疗目标的期望存在差异。
- 研究提示需持续让患者参与axSpA管理和决策讨论。
研究设计与样本
- 横断面调查,风湿科医生来自法国、德国、意大利、西班牙和英国,连续纳入其接下来8例成年axSpA患者。
- 医生问卷与患者自愿问卷配对比较;2023年6月至2024年6月共268名医生提供2165例患者数据,其中538例患者完成问卷。
主要发现
- 调查时患者仍有axSpA症状:晨僵35%、炎性背/髋/臀痛25%、疲劳25%,尽管77%已接受改善病情进阶治疗。
- 医患对调查时疾病严重度的加权一致率为86%(κ=0.515),对当前治疗满意度亦呈中度一致。
- 医生最常见治疗目标为达到低疾病活动度(76%),患者最常见目标为缓解疼痛(61%)。
- 医生将疗效不足、疼痛控制、 flare控制和残余疲劳列为治疗不满意原因。
关键数值与推荐
- 医患疾病严重度加权一致率86%,κ=0.515。
- 医生最常见治疗目标为低疾病活动度(76%),患者最常见目标为缓解疼痛(61%)。
- 77%患者已接受改善病情进阶治疗;35%有晨僵、25%有炎性背/髋/臀痛、25%有疲劳。
临床怎么用
- 在axSpA管理中应主动询问患者治疗目标,平衡医生追求低疾病活动度与患者缓解疼痛的期望。
- 即使患者已接受进阶治疗,仍需评估残余晨僵、炎性疼痛和疲劳,并据此讨论治疗满意度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the characteristics of axial spondyloarthritis (axSpA) and understand rheumatologists' and patients' experiences of axSpA management in a large real-world population using data from a cross-sectional survey. METHODS: Rheumatologists recruited from France, Germany, Italy, Spain, and the UK completed surveys for their next eight consulting adult patients with axSpA. The same patients were asked to voluntarily complete a survey, allowing rheumatologist- and patient-reported responses to be matched and compared. Surveys covered clinical status, symptoms and treatment decisions, preferences, and satisfaction. RESULTS: Between June 2023 and June 2024, 268 rheumatologists provided data on 2165 patients, 538 of whom completed the survey. At the time of the survey, patients continued to experience symptoms of axSpA (morning stiffness [35 %], inflammatory back, hip, or buttock pain [25 %], and fatigue [25 %]), despite 77 % having received disease-modifying advanced therapy. There was moderate agreement between patients and their rheumatologists on disease severity (86 % weighted agreement at the time of the survey, κ=0.515) and on their satisfaction with current treatment. The most common treatment target for rheumatologists was to achieve low disease activity (76 %), while the most common target for patients was to alleviate pain (61 %). Rheumatologists highlighted lack of efficacy, pain control, and flare control, and residual fatigue as reasons for treatment dissatisfaction. CONCLUSION: Patients and their rheumatologists were moderately aligned on their perception of disease severity and treatment satisfaction but differed in their expectations regarding treatment target. The study highlights the need for ongoing involvement of patients in discussions and decisions about axSpA management.
引用
- Baraliakos X, Navarro-Compán V, Nikiphorou E, et al. Rheumatologist and patient perspectives on axial spondyloarthritis management and treatment satisfaction in Europe. Semin Arthritis Rheum. 2025. PMID: 41406674. doi:10.1016/j.semarthrit.2025.152884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。